We are live on
!
Find out more
SCV
Sands Capital Ventures Portfolio holdings
AUM
$614M
1-Year Est. Return
19.92%
This Fund
S&P 500
This Quarter
Est. Return
-20.63%
1 Year Est. Return
+19.92%
3 Year Est. Return
+166.76%
5 Year Est. Return
+157.76%
10 Year Est. Return
–
AUM
$421M
AUM Growth
-$97.3M
(-19%)
Cap. Flow
+$73.4M
Cap. Flow
% of AUM
17.42%
Top 10 Holdings %
Top 10 Hldgs %
86.97%
Holding
21
New
1
Increased
5
Reduced
1
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGP
SpyGlass Pharma
SGP
|
+$67.3M |
| 2 |
DoorDash
DASH
|
+$2.89M |
| 3 |
Samsara
IOT
|
+$2.87M |
| 4 |
Coupang
CPNG
|
+$2.77M |
| 5 |
BBNX
Beta Bionics
BBNX
|
+$2.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$5.25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 40.53% |
| 2 | Technology | 28.67% |
| 3 | Financials | 22.3% |
| 4 | Consumer Discretionary | 8.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nu Holdings
NU
$73.2B
| $93.9M | 22.3% |
6,537,769
-323,630
| -5% | -$5.25M |
|
2
Klaviyo
KVYO
$5.26B
| $71M | 16.86% |
3,649,678
| – | – |
|
|
SGP
3
SpyGlass Pharma
SGP
$880M
| $64.8M | 15.38% |
+2,500,012
| New | +$67.3M |
|
|
BBNX
4
Beta Bionics
BBNX
$799M
| $37.2M | 8.82% |
3,708,043
+137,930
| +4% | +$2.04M |
|
5
Inhibikase Therapeutics
IKT
$377M
| $21.9M | 5.19% |
13,018,965
| – | – |
|
|
6
Coupang
CPNG
$29.1B
| $19.1M | 4.54% |
1,012,091
+141,667
| +16% | +$2.77M |
|
|
7
Samsara
IOT
$23.3B
| $17.8M | 4.22% |
560,287
+94,097
| +20% | +$2.87M |
|
|
8
DoorDash
DASH
$94.5B
| $16.7M | 3.97% |
111,231
+15,613
| +16% | +$2.89M |
|
|
BIOA
9
BioAge Labs
BIOA
$486M
| $13.8M | 3.27% |
786,353
| – | – |
|
10
10x Genomics
TXG
$7.39B
| $10.2M | 2.43% |
481,770
| – | – |
|
11
Datadog
DDOG
$91.4B
| $10.1M | 2.4% |
85,793
| – | – |
|
12
Acumen Pharmaceuticals
ABOS
$193M
| $8.78M | 2.08% |
3,720,105
+303,030
| +9% | +$773K |
|
13
Toast
TOST
$20.2B
| $8M | 1.9% |
301,647
| – | – |
|
14
Tarsus Pharmaceuticals
TARS
$3.05B
| $5.96M | 1.42% |
85,000
| – | – |
|
|
TTAN
15
ServiceTitan Inc
TTAN
$8.66B
| $5.7M | 1.35% |
89,856
| – | – |
|
16
monday.com
MNDY
$3.72B
| $4.69M | 1.11% |
67,868
| – | – |
|
17
Taysha Gene Therapies
TSHA
$1.89B
| $3.24M | 0.77% |
724,873
| – | – |
|
18
Snowflake
SNOW
$114B
| $3.05M | 0.73% |
20,253
| – | – |
|
19
Acrivon Therapeutics
ACRV
$83.9M
| $2.95M | 0.7% |
2,122,605
| – | – |
|
20
Candel Therapeutics
CADL
$863M
| $1.99M | 0.47% |
405,837
| – | – |
|
|
FIG
21
Figma
FIG
$13.6B
| $387K | 0.09% |
18,286
| – | – |
|
Similar funds
MCM
FFWA
PM
DCM
OWM
TCM
JHCP
DMC
Sands Capital Ventures's Q1 2026 Portfolio in Review
As of Q1 2026, Sands Capital Ventures held 21 positions worth $421M, down 19% from $518M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Sands Capital Ventures deployed $73.4M of net new capital in Q1 2026, opening 1 new position and adding to 5 existing holdings. Its largest new stake was SpyGlass Pharma: 2,500,012 shares worth $64.8M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 35% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Nu Holdings, an estimated $5.25M trimmed.
- Sands Capital Ventures's largest Q1 2026 buy was SpyGlass Pharma: 2,500,012 shares worth $64.8M.
- Sands Capital Ventures added most to DoorDash in Q1 2026, an estimated $2.89M increase.
- Sands Capital Ventures's biggest Q1 2026 reduction was Nu Holdings, cutting an estimated $5.25M.
- Sands Capital Ventures's ten largest holdings make up 87% of its $421M portfolio in Q1 2026.
- Sands Capital Ventures opened 1 new position and closed 0 in Q1 2026.
- Sands Capital Ventures's portfolio value fell 19% quarter-over-quarter to $421M.
Based on Sands Capital Ventures's 13F filing for Q1 2026, filed 8 May 2026.